Keywords: بهینه سازی سرب; Lead optimisation; Lipophilicity; Lipophilic ligand efficiency; Ligand efficiency;
مقالات ISI بهینه سازی سرب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بهینه سازی سرب; SYK; Spleen Tyrosine Kinase; Lead optimisation; Inhibitor; Skin penetration; Dermal;
Keywords: بهینه سازی سرب; Telaprevir (3010818); Lapatinib (208908); Ponatinib (24826799); Bedaquiline (5388906); Torcetrapib (159325); Dalcetrapib (6918540); Evacetrapib (49836058); Anaceptrapib (11556427); Physicochemical properties; Risk/benefit; Patented compounds; Impact of ti
Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT)
Keywords: بهینه سازی سرب; Benzoxaborole; Trypanosomiasis; Cattle; SAR; Lead optimisation; Protozoan;
Targeting the dengue β-OG with serotype-specific alkaloid virtual leads
Keywords: بهینه سازی سرب; Dengue virus; Virus-host fusion inhibitor; β-OG pocket; Serotype-specificity; Virtual lead; Virtual screening; Molecular docking; Lead optimisation;
Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors
Keywords: بهینه سازی سرب; SYK; Spleen Tyrosine Kinase; Selective; Potent; Orally bioavailable; Azanaphthyridine; Lead optimisation; Medicinal chemistry;
Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists
Keywords: بهینه سازی سرب; H3 receptor; Histamine; GPCR; Clinical candidate; Receptor antagonists; Neurotransmitters; Lead optimisation;
Hydantoin based inhibitors of MMP13—Discovery of AZD6605
Keywords: بهینه سازی سرب; MMP13; Hydantoin; Zinc binder; Cyp P450; Lead optimisation
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2
Keywords: بهینه سازی سرب; MMP13; Selectivity; Non-zinc binder; Lead Optimisation;
Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability
Keywords: بهینه سازی سرب; V1a antagonists; Triazoles; LiPE; Lead optimisation; Number of rotatable bonds
Optimisation of ITK inhibitors through successive iterative design cycles
Keywords: بهینه سازی سرب; Interleukin-2 inducible T cell kinase; Lead optimisation; In vivo testing; Anti-CD3 IL-2 mouse model
Synthesis and structure–activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor
Keywords: بهینه سازی سرب; P2X7; P2X7 antagonist; Lead optimisation
Identification of potent ITK inhibitors through focused compound library design including structural information
Keywords: بهینه سازی سرب; ITK; Interleukin-2 inducible T cell kinase; ITK inhibitors; Library design; Kinases; Drug design; Docking; Crystal structure; X-ray; Lead finding; Lead optimisation; Focused kinase library; Ligand efficiency
The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA α5 inverse agonists for the treatment of cognitive dysfunction
Keywords: بهینه سازی سرب; Neuroscience; GABAA receptor subtypes; Lead optimisation; Clinical candidate
Discovery and structure–activity relationships of pentanedioic acid diamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type I
Keywords: بهینه سازی سرب; Pentanedioic acid diamides; 11β-Hydroxysteroid dehydrogenase type I inhibitors; Rational drug design; Lead optimisation
Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode
Keywords: بهینه سازی سرب; Lead optimisation; Ligand docking; Induced fit; SAR